Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orchard Secures New Libmeldy Price In Germany

Executive Summary

Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.

You may also be interested in...

Orchard Will Launch Lenmeldy At Just Five Centers

Orchard, which Kyowa Kirin bought in October, gave Lenmeldy a $4.25m list price, exceeding the upper bound of about $3.9m set by ICER.

New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe

Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.

ICER Report Assumes $2.8m Price For Libmeldy As Orchard Gears Up For US Debut

The drug-pricing watchdog gave the gene therapy for metachromatic leukodystrophy an “A” grade for use in presymptomatic patients receiving the therapy, which already is approved in Europe.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts